Q3 2026 Advanced Enzyme Technologies Ltd Earnings Call Transcript

Feb 4, 2026 / 10:30 AM GMT

Release Date Price: ₹291.85 (+2.15%)

Transcript

Key Points

Positve

Advanced Enzyme Technologies Ltd (BOM:540025) reported a 2% year-on-year revenue growth for the quarter, indicating resilience despite global market disruptions.
The company achieved a 15% revenue growth on a year-to-date basis, showcasing strong performance over the nine-month period.
Profit after tax increased by 11% year-on-year and 20% on a year-to-date basis, reflecting improved profitability.
The animal healthcare segment showed robust growth with a 22% year-on-year increase and 26% growth on a year-to-date basis.
The bioprocessing segment recorded a 13% year-on-year growth, driven by a strong performance in the food business, which grew by 16% year-on-year.

Negative

The human healthcare segment, the largest revenue contributor, experienced a 6% year-on-year decline due to lower sales in the pharma API and nutrition business.
EBITDA for the quarter decreased by 11% year-on-year and 18% quarter-on-quarter, indicating pressure on operating margins.
The specialized manufacturing segment remained flat year-on-year and declined by 16% sequentially, highlighting challenges in this area.
The US market faced uncertainties due to tariffs, impacting sales and creating a challenging environment for growth.
The company experienced a decline in international sales, particularly in the human nutrition segment, due to market uncertainties and cost pressures.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ADEN.NS - Advanced Enzyme Technologies Ltd
Q3 2026 Advanced Enzyme Technologies Ltd Earnings Call
Feb 04, 2026 / 10:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good evening ladies and gentlemen. I'm Akash, moderator for the conference call. Welcome to Advanced Enzyme Technologies Limited Q3 and 91 FY26 earnings conference call. As a reminder, all participants will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing and then 0 on a touchstone telephone.

Please note this conference is being recorded. I would now like to hand over the floor to Mr.ronak Sharraf, manager in investor relations.

Thank you and over to you, sir.

-------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.